Express Scripts Stock Price, News & Analysis (NASDAQ:ESRX)

$80.87 0.78 (0.97 %)
(As of 01/16/2018 04:00 PM ET)
Previous Close$80.09
Today's Range$80.15 - $81.75
52-Week Range$55.80 - $81.75
Volume3.16 million shs
Average Volume3.96 million shs
Market Capitalization$45.80 billion
P/E Ratio13.43
Dividend YieldN/A
Beta0.87

About Express Scripts (NASDAQ:ESRX)

Express Scripts logoExpress Scripts, Inc. is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM). PBM segment’s services include retail network pharmacy management and retail drug card programs, home delivery services, specialty benefit services, patient care contact centers, benefit plan design and consultation, drug formulary management, compliance and therapy management programs, information reporting and analysis programs, rebate programs, and electronic claims processing and drug utilization review. EM segment’s services include distribution of pharmaceuticals and medical supplies to providers and clinics and healthcare account administration and implementation of consumer-directed healthcare solutions.

Receive ESRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ESRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Health Care Plans
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:ESRX
CUSIP30219G10
Phone314-996-0900

Debt

Debt-to-Equity Ratio0.86%
Current Ratio0.73%
Quick Ratio0.61%

Price-To-Earnings

Trailing P/E Ratio13.4335548172757
Forward P/E Ratio11.49
P/E Growth0.89

Sales & Book Value

Annual Sales$100.29 billion
Price / Sales0.46
Cash Flow$10.03 per share
Price / Cash8.06
Book Value$26.34 per share
Price / Book3.07

Profitability

Trailing EPS$6.02
Net Income$3.40 billion
Net Margins3.64%
Return on Equity25.46%
Return on Assets7.95%

Miscellaneous

Employees25,600
Outstanding Shares566,370,000

Express Scripts (NASDAQ:ESRX) Frequently Asked Questions

What is Express Scripts' stock symbol?

Express Scripts trades on the NASDAQ under the ticker symbol "ESRX."

How will Express Scripts' stock buyback program work?

Express Scripts declared that its board has approved a share repurchase program on Wednesday, December 20th 2017, which permits the company to repurchase 45,000,000 outstanding shares, according to EventVestor. This repurchase authorization permits the company to buy shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's board believes its stock is undervalued.

How were Express Scripts' earnings last quarter?

Express Scripts Holding (NASDAQ:ESRX) issued its earnings results on Tuesday, October, 24th. The company reported $1.90 EPS for the quarter, hitting analysts' consensus estimates of $1.90. The business earned $24.68 billion during the quarter, compared to analysts' expectations of $25.68 billion. Express Scripts had a return on equity of 25.46% and a net margin of 3.64%. The firm's quarterly revenue was down 2.9% on a year-over-year basis. During the same quarter last year, the firm posted $1.74 EPS. View Express Scripts' Earnings History.

When will Express Scripts make its next earnings announcement?

Express Scripts is scheduled to release their next quarterly earnings announcement on Tuesday, February, 13th 2018. View Earnings Estimates for Express Scripts.

What guidance has Express Scripts issued on next quarter's earnings?

Express Scripts issued an update on its fourth quarter earnings guidance on Tuesday, October, 24th. The company provided earnings per share (EPS) guidance of $2.03-2.11 for the period, compared to the Thomson Reuters consensus estimate of $2.04.

Where is Express Scripts' stock going? Where will Express Scripts' stock price be in 2018?

20 analysts have issued 1-year price objectives for Express Scripts' stock. Their forecasts range from $57.00 to $95.00. On average, they expect Express Scripts' stock price to reach $78.38 in the next twelve months. View Analyst Ratings for Express Scripts.

What are Wall Street analysts saying about Express Scripts stock?

Here are some recent quotes from research analysts about Express Scripts stock:

  • 1. According to Zacks Investment Research, "We are upbeat about Express Scripts’ pharmacy-benefits management long-term outlook. The projection takes the volatile healthcare market trends, inflation, patent expiration and lower industry utilization growth into consideration. Furthermore, Express Scripts should benefit from increased generic utilization, shift toward mail orders, strong specialty growth and an aging population. Branded drugs are becoming increasingly expensive due to double-digit brand inflation. Thus, continued rise in the price of specialty drugs and overwhelming regulatory burden is opening up considerable prospects for generics. However, over the past one year, Express Scripts has underperformed the broader industry in terms of price. Tough competition in the niche space and the persistent drug pricing issue are anticipated to affect the stock." (10/24/2017)
  • 2. Jefferies Group LLC analysts commented, "We believe ESRX remains a Buy given our view that company fundamentals, including its FCF, are stable and that the stock's valuation is attractive at 9x FY18 P/E. That said, we recognize that headlines surrounding drug pricing pressure and the overhang from ESRX's Anthem contract will drive continued stock volatility NT." (2/17/2017)

Are investors shorting Express Scripts?

Express Scripts saw a decline in short interest during the month of December. As of December 29th, there was short interest totalling 24,339,526 shares, a decline of 15.5% from the December 15th total of 28,815,988 shares. Based on an average daily volume of 3,210,497 shares, the short-interest ratio is currently 7.6 days. Currently, 4.3% of the shares of the company are sold short.

Who are some of Express Scripts' key competitors?

Who owns Express Scripts stock?

Express Scripts' stock is owned by many different of retail and institutional investors. Top institutional investors include Factory Mutual Insurance Co. (0.10%), Hexavest Inc. (0.09%), Country Trust Bank (0.06%), DnB Asset Management AS (0.06%), Nisa Investment Advisors LLC (0.04%) and Hikari Power Ltd (0.02%). Company insiders that own Express Scripts stock include Christine Houston, Christopher A Mcginnis, Everett Neville, Glen D Stettin, Mahon Thomas P Mac, Phyllis S Anderson, Timothy C Wentworth and Woodrow A Myers Jr. View Institutional Ownership Trends for Express Scripts.

Who sold Express Scripts stock? Who is selling Express Scripts stock?

Express Scripts' stock was sold by a variety of institutional investors in the last quarter, including Factory Mutual Insurance Co., Exxonmobil Investment Management Inc. TX, Addenda Capital Inc., Liberty Capital Management Inc., Chesley Taft & Associates LLC, First National Bank of Mount Dora Trust Investment Services, Louisiana State Employees Retirement System and Norway Savings Bank. Company insiders that have sold Express Scripts company stock in the last year include Christine Houston, Everett Neville, Glen D Stettin, Phyllis S Anderson and Woodrow A Myers Jr. View Insider Buying and Selling for Express Scripts.

Who bought Express Scripts stock? Who is buying Express Scripts stock?

Express Scripts' stock was bought by a variety of institutional investors in the last quarter, including Oliver Luxxe Assets LLC, Hikari Power Ltd, Aurora Investment Counsel, Nisa Investment Advisors LLC, DnB Asset Management AS, Sawyer & Company Inc, Polianta Ltd and Hexavest Inc.. View Insider Buying and Selling for Express Scripts.

How do I buy Express Scripts stock?

Shares of Express Scripts can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Express Scripts' stock price today?

One share of Express Scripts stock can currently be purchased for approximately $80.87.

How big of a company is Express Scripts?

Express Scripts has a market capitalization of $45.80 billion and generates $100.29 billion in revenue each year. The company earns $3.40 billion in net income (profit) each year or $6.02 on an earnings per share basis. Express Scripts employs 25,600 workers across the globe.

How can I contact Express Scripts?

Express Scripts' mailing address is ONE EXPRESS WAY, ST. LOUIS MO, 63121. The company can be reached via phone at 314-996-0900 or via email at [email protected]


MarketBeat Community Rating for Express Scripts (ESRX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  679 (Vote Outperform)
Underperform Votes:  455 (Vote Underperform)
Total Votes:  1,134
MarketBeat's community ratings are surveys of what our community members think about Express Scripts and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Express Scripts (NASDAQ:ESRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.202.202.052.12
Ratings Breakdown: 3 Sell Rating(s)
10 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
10 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
11 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
9 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $78.38$75.08$68.50$70.75
Price Target Upside: 2.13% downside4.93% upside9.85% upside15.21% upside

Express Scripts (NASDAQ:ESRX) Consensus Price Target History

Price Target History for Express Scripts (NASDAQ:ESRX)

Express Scripts (NASDAQ:ESRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/12/2018SunTrust BanksReiterated RatingBuy$95.00LowView Rating Details
1/9/2018Robert W. BairdReiterated RatingOutperform -> Buy$81.00 -> $92.00N/AView Rating Details
1/4/2018Evercore ISIInitiated CoverageIn -> In-Line$78.00LowView Rating Details
12/21/2017Needham & Company LLCReiterated RatingHoldLowView Rating Details
12/15/2017Jefferies GroupSet Price TargetBuy$80.00HighView Rating Details
12/15/2017Royal Bank of CanadaSet Price TargetHold$68.00HighView Rating Details
12/15/2017Raymond James FinancialReiterated RatingSellLowView Rating Details
12/14/2017Maxim GroupBoost Price TargetBuy$78.00 -> $87.00LowView Rating Details
12/6/2017Sanford C. BernsteinUpgradeUnderperform -> Market PerformLowView Rating Details
12/4/2017Deutsche BankInitiated CoverageBuy$75.00HighView Rating Details
10/24/2017MizuhoSet Price TargetHold$67.00N/AView Rating Details
8/10/2017Morgan StanleyBoost Price TargetUnderweight$52.00 -> $57.00LowView Rating Details
6/9/2017CowenReiterated RatingOutperform$83.00LowView Rating Details
4/26/2017Edward JonesDowngradeBuy -> HoldHighView Rating Details
4/25/2017Bank of AmericaReiterated RatingNeutral$77.00HighView Rating Details
3/29/2017ArgusReiterated RatingHoldLowView Rating Details
3/15/2017Wells Fargo & CoDowngradeMarket Perform -> UnderperformLowView Rating Details
3/8/2017Leerink SwannReiterated RatingMarket Perform$75.00LowView Rating Details
2/16/2017Credit Suisse GroupReiterated RatingBuy$85.00N/AView Rating Details
2/14/2017OppenheimerReiterated RatingHoldN/AView Rating Details
12/16/2016BarclaysReiterated RatingOverweightN/AView Rating Details
6/1/2016WedbushReiterated RatingNeutralN/AView Rating Details
5/24/2016CitigroupReiterated RatingBuyN/AView Rating Details
4/27/2016FBR & CoLower Price TargetMkt Perform$90.00 -> $75.00N/AView Rating Details
3/18/2016William BlairReiterated RatingBuyN/AView Rating Details
2/18/2016Goldman Sachs GroupLower Price TargetNeutral$82.00 -> $74.00N/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Express Scripts (NASDAQ:ESRX) Earnings History and Estimates Chart

Earnings by Quarter for Express Scripts (NASDAQ:ESRX)

Express Scripts (NASDAQ ESRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/12/2018$2.06N/AView Earnings Details
10/24/2017Q3 2017$1.90$1.90$25.68 billion$24.68 billionViewN/AView Earnings Details
7/25/2017Q2 2017$1.71$1.73$25.52 billion$25.35 billionViewN/AView Earnings Details
4/24/2017Q1 17$1.32$1.33$24.95 billion$24.65 billionViewN/AView Earnings Details
2/14/2017Q4 2016$1.87$1.88$26.31 billion$24.90 billionViewListenView Earnings Details
10/25/2016Q3$1.74$1.74$25.48 billion$25.41 billionViewListenView Earnings Details
7/25/2016Q216$1.57$1.57$25.42 billion$25.20 billionViewListenView Earnings Details
4/25/2016Q1$1.22$1.22$25.20 billion$24.80 billionViewListenView Earnings Details
2/16/2016Q4$1.56$1.56$26.58 billion$26.18 billionViewListenView Earnings Details
10/27/2015Q315$1.44$1.45$26.38 million$25.22 millionViewListenView Earnings Details
7/28/2015Q215$1.40$1.44$26.13 billion$25.45 billionViewListenView Earnings Details
4/28/2015Q115$1.10$1.10$24.34 billion$24.90 billionViewListenView Earnings Details
2/23/2015Q414$1.38$1.39$25.68 billion$26.31 billionViewListenView Earnings Details
10/28/2014Q314$1.29$1.29$24.93 billion$25.78 billionViewListenView Earnings Details
7/29/2014Q214$1.22$1.23$24.42 billion$25.11 billionViewListenView Earnings Details
4/29/2014Q114$1.01$0.99$23.81 billion$23.69 billionViewListenView Earnings Details
2/20/2014Q413$1.12$1.12$25.49 billion$25.78 billionViewN/AView Earnings Details
10/25/2013Q313$1.08$1.08$25.01 billion$25.92 billionViewListenView Earnings Details
7/29/2013Q2 2013$1.10$1.12$25.51 billion$26.40 billionViewListenView Earnings Details
4/29/2013Q1 2013$0.97$0.99$25.55 billion$26.06 billionViewListenView Earnings Details
2/18/2013Q4 2012$1.04$1.05$27.24 billion$27.41 billionViewListenView Earnings Details
11/5/2012Q312$0.99$1.02$27.48 billion$27.00 billionViewN/AView Earnings Details
8/7/2012$0.82$0.88ViewN/AView Earnings Details
5/10/2012$0.77$0.73ViewN/AView Earnings Details
2/22/2012$0.85$0.82ViewN/AView Earnings Details
10/25/2011$0.77$0.79ViewN/AView Earnings Details
7/21/2011$0.69$0.71ViewN/AView Earnings Details
4/26/2011$0.69$0.66ViewN/AView Earnings Details
2/16/2011$0.70$0.71ViewN/AView Earnings Details
10/27/2010Q3 2010$0.65$0.65ViewN/AView Earnings Details
7/28/2010Q2 2010$0.59$0.60ViewN/AView Earnings Details
4/28/2010Q1 2010$0.55$0.55ViewN/AView Earnings Details
2/24/2010Q4 2009$0.45$0.49ViewN/AView Earnings Details
10/28/2009Q3 2009$0.41$0.40ViewN/AView Earnings Details
7/29/2009Q2 2009$0.44$0.44ViewN/AView Earnings Details
4/29/2009Q1 2009$0.41$0.43ViewN/AView Earnings Details
2/25/2009Q4 2008$0.42$0.41ViewN/AView Earnings Details
10/30/2008Q3 2008$0.39$0.41ViewN/AView Earnings Details
7/30/2008Q2 2008$0.36$0.38ViewN/AView Earnings Details
4/29/2008Q1 2008$0.34$0.35ViewN/AView Earnings Details
2/21/2008Q4 2007$0.32$0.34ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Express Scripts (NASDAQ:ESRX) Earnings Estimates

2018 EPS Consensus Estimate: $8.04
2019 EPS Consensus Estimate: $9.59
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20185$1.46$1.93$1.58
Q2 20185$1.86$2.37$1.98
Q3 20185$2.03$2.44$2.14
Q4 20185$2.19$2.63$2.34
Q1 20192$1.58$2.17$1.88
Q2 20192$2.09$2.49$2.29
Q3 20192$2.26$2.68$2.47
Q4 20191$2.95$2.95$2.95
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Express Scripts (NASDAQ:ESRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Express Scripts (NASDAQ ESRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.68%
Institutional Ownership Percentage: 88.21%
Insider Trades by Quarter for Express Scripts (NASDAQ:ESRX)
Institutional Ownership by Quarter for Express Scripts (NASDAQ:ESRX)

Express Scripts (NASDAQ ESRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/11/2018Glen D StettinVPSell3,449$81.00$279,369.0033,715View SEC Filing  
1/2/2018Glen D StettinVPSell3,448$76.00$262,048.00View SEC Filing  
12/15/2017Christine HoustonVPSell10,104$70.08$708,088.3287,400View SEC Filing  
11/1/2017Phyllis S. AndersonVPSell643$62.37$40,103.91View SEC Filing  
10/31/2017Timothy C WentworthCEOBuy8,000$61.13$489,040.0098,628View SEC Filing  
9/11/2017Woodrow A Myers JrDirectorSell3,900$63.93$249,327.0011,500View SEC Filing  
9/8/2017Phyllis S AndersonVPSell578$63.13$36,489.1410,530View SEC Filing  
8/23/2017Everett NevilleVPSell1,163$61.48$71,501.2418,232View SEC Filing  
5/19/2017Phyllis S AndersonVPSell1,100$60.08$66,088.0011,108View SEC Filing  
3/1/2017Everett NevilleSVPSell2,352$70.16$165,016.3211,287View SEC Filing  
1/3/2017Everett NevilleVPSell1,123$69.41$77,947.4312,712View SEC Filing  
9/14/2016Woodrow A Myers JrDirectorSell12,036$70.40$847,334.4014,918View SEC Filing  
9/12/2016Christopher A McginnisVPSell1,785$70.77$126,324.454,955View SEC Filing  
5/10/2016Everett NevilleVPSell800$74.11$59,288.0013,835View SEC Filing  
4/29/2016Mahon Thomas P MacDirectorSell5,482$73.93$405,284.2655,689View SEC Filing  
3/10/2016Christopher A McginnisVPSell579$68.56$39,696.246,508View SEC Filing  
3/7/2016Phyllis S AndersonVPSell614$71.14$43,679.964,346View SEC Filing  
2/29/2016Everett NevilleVPSell4,323$71.00$306,933.0011,126View SEC Filing  
6/9/2015Gary WimberlyVPSell1,644$87.14$143,258.16View SEC Filing  
6/1/2015Gary WimberlyVPSell46,069$86.15$3,968,844.35View SEC Filing  
3/2/2015Glen D StettinVPSell2,674$84.39$225,658.86View SEC Filing  
2/25/2015Glen D StettinVPSell27,603$87.55$2,416,642.65View SEC Filing  
12/2/2014Keith J EblingVPSell10,000$84.25$842,500.00View SEC Filing  
12/1/2014Steven B MillerVPSell4,896$83.57$409,158.72View SEC Filing  
11/28/2014Glen D StettinVPSell10,800$82.96$895,968.00View SEC Filing  
11/17/2014John O ParkerDirectorSell25,822$78.75$2,033,482.50View SEC Filing  
11/7/2014Maura C BreenDirectorSell13,128$77.80$1,021,358.40View SEC Filing  
9/5/2014Edward B IgnaczakEVPSell9,886$75.28$744,218.08View SEC Filing  
8/28/2014Seymour SternbergDirectorSell15,508$74.12$1,149,452.96View SEC Filing  
8/25/2014Keith J EblingVPSell10,000$75.50$755,000.00View SEC Filing  
8/5/2014Gary G BenanavDirectorSell12,694$70.82$898,989.08View SEC Filing  
8/5/2014Sara E WadeVPSell20,000$70.44$1,408,800.00View SEC Filing  
8/4/2014David A NortonVPSell1,276$71.02$90,621.52View SEC Filing  
8/1/2014Maura C BreenDirectorSell12,694$69.94$887,818.36View SEC Filing  
6/13/2014George PazCEOSell681,508$71.21$48,530,184.68View SEC Filing  
3/11/2014Keith EblingVPSell25,721$78.69$2,023,985.4922,222View SEC Filing  
3/10/2014Patrick McnameeCOOSell68,425$78.28$5,356,309.0012,421View SEC Filing  
3/10/2014Steven MillerVPSell12,664$77.96$987,285.4421,417View SEC Filing  
3/7/2014Keith EblingVPSell295,367$77.29$22,828,915.4328,460View SEC Filing  
1/9/2014Nicholas LahowchicDirectorSell7,650$72.00$550,800.0024,903View SEC Filing  
12/26/2013Nicholas LahowchicDirectorSell12,694$70.00$888,580.0024,903View SEC Filing  
11/5/2013Mahon Thomas MacDirectorSell10,251$63.20$647,863.2039,881View SEC Filing  
9/9/2013Maura C BreenDirectorSell10,527$64.12$674,991.24View SEC Filing  
9/4/2013Woodrow Myers, Jr.DirectorSell7,128$64.66$460,896.489,698View SEC Filing  
7/19/2013Nicholas LahowchicDirectorSell20,377$66.26$1,350,180.02View SEC Filing  
6/11/2013Woodrow A Myers JrDirectorSell1,750$62.57$109,497.50View SEC Filing  
5/28/2013Woodrow A Myers JrDirectorSell2,000$63.75$127,500.00View SEC Filing  
5/15/2013Jeffrey HallCFOSell13,307$61.13$813,456.91View SEC Filing  
5/8/2013Woodrow A Myers JrDirectorSell13,462$61.22$824,143.64View SEC Filing  
5/1/2013Keith J EblingEVPSell59,494$59.58$3,544,652.52View SEC Filing  
4/30/2013Patrick McnameeCOOSell271,972$59.65$16,223,129.80View SEC Filing  
3/14/2013Mahon Thomas P MacDirectorBuy5,000$59.58$297,900.00View SEC Filing  
9/4/2012Jeffrey HallCFOSell75,000$62.81$4,710,750.00View SEC Filing  
8/8/2012Edward B IgnaczakEVPSell115,466$59.33$6,850,597.78View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Express Scripts (NASDAQ ESRX) News Headlines

Source:
DateHeadline
Express Scripts Holding Company Announces Fourth Quarter and Full Year 2017 Earnings Conference CallExpress Scripts Holding Company Announces Fourth Quarter and Full Year 2017 Earnings Conference Call
feeds.benzinga.com - January 15 at 2:37 PM
Express Scripts 90-Day Analysis of Opioid Management Positive - NasdaqExpress Scripts 90-Day Analysis of Opioid Management Positive - Nasdaq
www.nasdaq.com - January 15 at 9:39 AM
Express Scripts 90-Day Analysis of Opioid Management PositiveExpress Scripts 90-Day Analysis of Opioid Management Positive
finance.yahoo.com - January 15 at 9:39 AM
Express Scripts (ESRX) Rating Reiterated by SunTrust BanksExpress Scripts (ESRX) Rating Reiterated by SunTrust Banks
www.americanbankingnews.com - January 14 at 12:38 AM
Express Scripts Holding (ESRX) Short Interest Down 15.5% in DecemberExpress Scripts Holding (ESRX) Short Interest Down 15.5% in December
www.americanbankingnews.com - January 13 at 2:04 AM
Express Scripts Holding (ESRX) VP Glen D. Stettin Sells 3,449 SharesExpress Scripts Holding (ESRX) VP Glen D. Stettin Sells 3,449 Shares
www.americanbankingnews.com - January 12 at 6:58 PM
Express Scripts Holding Expected to Post Q1 2018 Earnings of $1.93 Per Share (ESRX)Express Scripts Holding Expected to Post Q1 2018 Earnings of $1.93 Per Share (ESRX)
www.americanbankingnews.com - January 11 at 10:00 AM
A Look At The Fair Value Of Express Scripts Holding Company (NASDAQ:ESRX)A Look At The Fair Value Of Express Scripts Holding Company (NASDAQ:ESRX)
finance.yahoo.com - January 10 at 9:49 AM
Express Scripts Accredo Earns Renewed URAC Specialty Pharmacy AccreditationExpress Scripts' Accredo Earns Renewed URAC Specialty Pharmacy Accreditation
finance.yahoo.com - January 10 at 9:49 AM
Inside Rx En Español: Company Launches Spanish Language Website for Consumers Seeking Discounts on Prescription MedicationsInside Rx En Español: Company Launches Spanish Language Website for Consumers Seeking Discounts on Prescription Medications
finance.yahoo.com - January 10 at 9:49 AM
Express Scripts Hits 80-Plus Relative Strength Rating BenchmarkExpress Scripts Hits 80-Plus Relative Strength Rating Benchmark
finance.yahoo.com - January 9 at 5:11 PM
Express Scripts CEO Says PBM Is a Value CreatorExpress Scripts CEO Says PBM Is a Value Creator
finance.yahoo.com - January 9 at 5:11 PM
Express Scripts CEO Welcomes Opportunity to Work With AmazonExpress Scripts CEO Welcomes Opportunity to Work With Amazon
finance.yahoo.com - January 9 at 5:11 PM
Why Express Scripts Holding Company Broke Out in December - Motley FoolWhy Express Scripts Holding Company Broke Out in December - Motley Fool
www.fool.com - January 8 at 10:01 AM
Why Express Scripts Holding Company Broke Out in DecemberWhy Express Scripts Holding Company Broke Out in December
www.fool.com - January 7 at 7:23 AM
Express Scripts Holding (ESRX) VP Glen D. Stettin Sells 3,448 SharesExpress Scripts Holding (ESRX) VP Glen D. Stettin Sells 3,448 Shares
www.americanbankingnews.com - January 4 at 7:56 PM
Express Scripts (ESRX) Research Coverage Started at Evercore ISIExpress Scripts (ESRX) Research Coverage Started at Evercore ISI
www.americanbankingnews.com - January 4 at 5:12 PM
Spark Therapeutics Hopes to Cure a Rare Blindness for $850,000 a PopSpark Therapeutics Hopes to Cure a Rare Blindness for $850,000 a Pop
finance.yahoo.com - January 4 at 9:41 AM
Express Scripts Holding (ESRX) Expected to Post Quarterly Sales of $25.13 BillionExpress Scripts Holding (ESRX) Expected to Post Quarterly Sales of $25.13 Billion
www.americanbankingnews.com - January 4 at 8:52 AM
A US drugmaker offers to cure rare blindness for $850,000A US drugmaker offers to cure rare blindness for $850,000
finance.yahoo.com - January 3 at 5:11 PM
Spark Therapeutics Sets Price Of Blindness-Curing Gene Therapy At $850,000Spark Therapeutics Sets Price Of Blindness-Curing Gene Therapy At $850,000
finance.yahoo.com - January 3 at 8:53 AM
Express Scripts Holding Company to Present at the J.P. Morgan Healthcare ConferenceExpress Scripts Holding Company to Present at the J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 6:25 PM
$2.08 Earnings Per Share Expected for Express Scripts Holding (ESRX) This Quarter$2.08 Earnings Per Share Expected for Express Scripts Holding (ESRX) This Quarter
www.americanbankingnews.com - January 2 at 5:12 PM
Short Interest in Express Scripts Holding (ESRX) Declines By 6.3%Short Interest in Express Scripts Holding (ESRX) Declines By 6.3%
www.americanbankingnews.com - December 30 at 2:34 AM
Express Scripts: How Its Performance Contributed to Its ValuationExpress Scripts: How Its Performance Contributed to Its Valuation
finance.yahoo.com - December 28 at 3:46 PM
Technical Perspectives on Health Insurance Innovations, Express Scripts, Centene, and Aetna - PR Newswire (press release)Technical Perspectives on Health Insurance Innovations, Express Scripts, Centene, and Aetna - PR Newswire (press release)
www.prnewswire.com - December 28 at 7:26 AM
Will Express Scripts Holding Company’s (NASDAQ:ESRX) Earnings Grow Over The Next Few Years?Will Express Scripts Holding Company’s (NASDAQ:ESRX) Earnings Grow Over The Next Few Years?
finance.yahoo.com - December 28 at 7:26 AM
Express Scripts Holding Company (ESRX) Given Average Recommendation of "Hold" by BrokeragesExpress Scripts Holding Company (ESRX) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - December 26 at 11:52 AM
Express Scripts (ESRX) Upgraded to Strong-Buy at BidaskClubExpress Scripts (ESRX) Upgraded to Strong-Buy at BidaskClub
www.americanbankingnews.com - December 23 at 2:10 PM
ETFs with exposure to Express Scripts Holding Co. : December 21, 2017ETFs with exposure to Express Scripts Holding Co. : December 21, 2017
finance.yahoo.com - December 21 at 5:08 PM
Express Scripts (ESRX) Rating Reiterated by Needham & Company LLCExpress Scripts (ESRX) Rating Reiterated by Needham & Company LLC
www.americanbankingnews.com - December 21 at 3:06 PM
Express Scripts (ESRX) Board Declares Share Repurchase PlanExpress Scripts (ESRX) Board Declares Share Repurchase Plan
www.americanbankingnews.com - December 20 at 12:04 PM
Express Scripts Getting Closer To Key Technical BenchmarkExpress Scripts Getting Closer To Key Technical Benchmark
finance.yahoo.com - December 19 at 5:06 PM
Express Scripts Holding Company (ESRX) VP Christine Houston Sells 10,104 SharesExpress Scripts Holding Company (ESRX) VP Christine Houston Sells 10,104 Shares
www.americanbankingnews.com - December 18 at 8:38 PM
Express Scripts Buys eviCore for $3.6B, Forays Into MBMExpress Scripts Buys eviCore for $3.6B, Forays Into MBM
finance.yahoo.com - December 18 at 10:02 AM
SunTrust Banks Analysts Lift Earnings Estimates for Express Scripts Holding Company (ESRX)SunTrust Banks Analysts Lift Earnings Estimates for Express Scripts Holding Company (ESRX)
www.americanbankingnews.com - December 18 at 4:56 AM
Express Scripts Holding Company Forecasted to Earn FY2017 Earnings of $7.04 Per Share (ESRX)Express Scripts Holding Company Forecasted to Earn FY2017 Earnings of $7.04 Per Share (ESRX)
www.americanbankingnews.com - December 18 at 2:54 AM
FY2017 EPS Estimates for Express Scripts Holding Company Increased by William Blair (ESRX)FY2017 EPS Estimates for Express Scripts Holding Company Increased by William Blair (ESRX)
www.americanbankingnews.com - December 18 at 2:30 AM
Express Scripts (ESRX) Stock Rating Upgraded by BidaskClubExpress Scripts (ESRX) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - December 17 at 6:30 AM
Jefferies Group Reiterates $80.00 Price Target for Express Scripts (ESRX)Jefferies Group Reiterates $80.00 Price Target for Express Scripts (ESRX)
www.americanbankingnews.com - December 16 at 10:16 AM
Express Scripts (ESRX) Receives Hold Rating from Royal Bank of CanadaExpress Scripts (ESRX) Receives Hold Rating from Royal Bank of Canada
www.americanbankingnews.com - December 16 at 6:28 AM
Express Scripts (ESRX) PT Set at $82.00 by SunTrust BanksExpress Scripts (ESRX) PT Set at $82.00 by SunTrust Banks
www.americanbankingnews.com - December 15 at 9:18 PM
Express Scripts Closes Acquisition Of eviCore; Companies Unite To Improve Healthcare For 100 Million AmericansExpress Scripts Closes Acquisition Of eviCore; Companies Unite To Improve Healthcare For 100 Million Americans
finance.yahoo.com - December 15 at 5:40 PM
Express Scripts (ESRX) Upgraded at Robert W. BairdExpress Scripts (ESRX) Upgraded at Robert W. Baird
www.americanbankingnews.com - December 15 at 4:24 PM
Express Scripts (ESRX) Stock Rating Reaffirmed by Raymond James FinancialExpress Scripts (ESRX) Stock Rating Reaffirmed by Raymond James Financial
www.americanbankingnews.com - December 15 at 3:38 PM
Express Scripts (ESRX) Raises FY17 EPS Guidance, FY18 EPS Guidance Tops Consensus - StreetInsider.comExpress Scripts (ESRX) Raises FY17 EPS Guidance, FY18 EPS Guidance Tops Consensus - StreetInsider.com
www.streetinsider.com - December 14 at 5:41 PM
Maxim Group Increases Express Scripts (ESRX) Price Target to $87.00Maxim Group Increases Express Scripts (ESRX) Price Target to $87.00
www.americanbankingnews.com - December 14 at 4:12 PM
Express Scripts Lifts 2017 Adj. EPS ViewExpress Scripts Lifts 2017 Adj. EPS View
www.nasdaq.com - December 14 at 9:51 AM
Express Scripts forecast 2018 profit above estimates, shares riseExpress Scripts forecast 2018 profit above estimates, shares rise
finance.yahoo.com - December 14 at 9:51 AM
Express Scripts 2018 earnings forecast above estimatesExpress Scripts 2018 earnings forecast above estimates
finance.yahoo.com - December 14 at 9:51 AM

SEC Filings

Express Scripts (NASDAQ:ESRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Express Scripts (NASDAQ:ESRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Express Scripts (NASDAQ ESRX) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.